title: How mechanical circulatory support helps not to need it--new strategies in pediatric heart failure.
abstract: During the past 3 years, seven potential candidates for mechanical circulatory support (MCS) were treated at our center. Ultimately, only one of them needed MCS (extracorporeal membrane oxygenation [ECMO] for 16 days), although 5 years earlier, all would have been considered for MCS at our center. Seven consecutive patients were seen in this period: four toddlers (three suffering from fulminant myocarditis and one with dilated cardiomyopathy associated with spongy myocardium) and three adolescents (two with postmyocarditis cardiomyopathy and one with hypertrophic cardiomyopathy and severe restrictive dysfunction after an ischemic event with cardiopulmonary resuscitation [stunned heart]). All patients presented in acute cardiocirculatory decompensation. All were admitted to the intensive care unit (ICU); all but one were sedated and intubated. A combination of levosimendan, milrinone, and nesiritide was administered to all patients. Use of catecholamines was kept short (<48 h in six individuals). MCS (ECMO, Berlin Heart Excor Pediatric, and Heartware) was always available. MCS initiation was indicated in only one patient, who was developing progressive multiorgan failure (MOF). The three toddlers with myocarditis recovered with complete normalization of myocardial function within 6 months. The fourth toddler is still at the ICU while waiting for transplantation. The three adolescents were listed with high urgency for heart transplantation, and all received a graft within 3 weeks. The adolescent with the stunned heart developed progressive MOF and was successfully supported with ECMO until transplantation. All six patients with completed course were discharged home in New York Heart Association Heart Failure Functional Classification System I condition without neurological deficits. Combined use of levosimendan, milrinone, and nesiritide, avoidance of catecholamines as much as possible, and MCS as backup are the new strategies at our center. This cardioprotective approach gives excellent outcome at lower risk and better cost-effectiveness in our pediatric patients with acute heart failure. Pediatric trials are recommended to evaluate combined use of newer cardioprotective drugs.
authors.affiliation: Department of Pediatrics III, Cardiology, Innsbruck Medical University Hospital, Innsbruck, Austria. ulrich.schweigmann@i-med.ac.at
authors.forename: Ulrich
authors.initials: U
authors.lastname: Schweigmann
authors.forename: Corinna
authors.initials: C
authors.lastname: Velik-Salchner
authors.forename: Juliane
authors.initials: J
authors.lastname: Kilo
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Schermer
mesh_terms: D000293:Adolescent; D009202:Cardiomyopathies / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002395:Catecholamines / Q000627:therapeutic use; D002675:Child, Preschool; D015199:Extracorporeal Membrane Oxygenation / Q000379:methods*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use; D007223:Infant; D008297:Male; D020105:Milrinone / Q000627:therapeutic use; D009205:Myocarditis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D045283:Natriuretic Agents / Q000627:therapeutic use; D020097:Natriuretic Peptide, Brain / Q000627:therapeutic use; D011724:Pyridazines / Q000627:therapeutic use; D000077464:Simendan
chemical_list: D002316:Cardiotonic Agents; D002395:Catecholamines; D006835:Hydrazones; D045283:Natriuretic Agents; D011724:Pyridazines; D020097:Natriuretic Peptide, Brain; D000077464:Simendan; D020105:Milrinone